 |
 |
||||||||
|
|||||||||
|
|||||||||
 |
 |
||||||||
|
Articles
Developing Novel Oral Drugs that Reduce Inflammation and Prevent Neurodegeneration, Paratek’s Evolving Co-Development Collaboration with Serono.
Strategies for Structure-Based Drug Design, Mark D. Weiss, Genetic Engineering News, Vol. 22, No. 7, April 1, 2002, 16,19 The Antibiotic Paradox. How the Misuse of Antibiotics Destroys Their Curative Powers (Second Edition), Stuart B. Levy, M.D., 2002, Perseus Publishing, Cambridge, MA. Tetracyclines in Biology, Chemistry and Medicine, M. Nelson, W. Hillen, R.A.Greenwald (Eds.), 2001, Birkhauser, Basel, SWITZERLAND. The crystal structure of MarR, a regulator of multiple antibiotic resistance, at 2.3 Å resolution, Michael N. Alekshun, Stuart B. Levy, Tanya R. Mealy, Barbara A. Seaton and James F. Head, Nature Structural Biology, Vol. 8, No. 8, August 2001, 710-714 “Living with the enemy,” New Scientist, June 2, 2001, 10-11 “The line of least resistance,” The Economist, May 5, 2001, 97-98 “The Antibiotics Crisis,” J. Madeleine Nash, TIME, January 15, 2001 Antibacterial household products: cause for concern, Stuart B. Levy, Emerging Infectious Diseases, 2001, 7 (suppl. 3): 512-515 Antibiotic resistance: consequences of inaction, Stuart B. Levy, Clinical Infectious Disease, 2001, 33: S124-S129 “How Germ-Phobia Can Lead to Illness,” The New York Times, June 20, 2000 “Antibiotics and the doomsday bug - fact or fiction?,” Bryan Appleyard, The Sunday Times Magazine, February 20, 2000, 48-52 “Staph can beat Drug,” The Boston Globe, January 7, 2000, A12 Bacterial drug resistance: response to survival threats, Michael N. Alekshun and Stuart B. Levy, in Bacterial Stress Responses, ed. by G. Storz and R. Hengge-Aronis, 2000, American Society for Microbiology, Washington DC, 323-366 Ineffectiveness of Topoisomerase Mutations in Mediating Clinically Significant Fluoroquinolone Resistance in Escherichia coli in absence of the AcrAB Efflux pump, Margret Oethinger, Winfred V. Kern, Angelika S. Jellen-Ritter, Laura M. McMurry, Stuart B. Levy, Antimicrobial agents and chemotherapy, Vol. 44, No. 1, January 2000, 10-13 Tetracycline resistance in Gram Positive bacteria, Laura McMurry and Stuart B. Levy, Gram-positive Pathogens, ed. By V.A. Fischetti et al, 2000 American Society for Microbiology, Washington DC, 660-672 “Resistance fighters,” The Boston Globe, November 1, 1999, C1,C4 The Mar regulon: multiple resistance to antibiotics and other toxic chemicals, Michael N. Alekshun and Stuart B. Levy, Trends in Microbiology, Vol. 7, No. 10, October 1999, 410-412 “Top-flight backing gives Hub biotech high hopes,” Boston Business Journal, Vol. 19, No. 29, September 2, 1999 Glaxo/Paratek in Antibiotics Deal, Scrip Pharmaceutical News, August 4, 1999 Glaxo agenerase posts $16M in first two months of marketing, The Pink Sheet-Prescription Pharmaceuticals and Biotechnology, August 2, 1999, 18-19 Paratek Pharmaceuticals, Inc., Biocentury, August 2, 1999 GlaxoWellcome forms deal with Hub’s Paratek, The Boston Globe, July 29, 1999 “Paratek Signs $95 M Deal In Antibiotics With GlaxoWellcome SmithKline Beecham,” BioWorld Today, July 29, 1999 “Glaxo, SmithKline Plan Collaborations,” The Wall Street Journal, July 28, 1999 Reversal of Tetracycline Resistance Mediated by Different Bacterial Tetracycline Resistance Determinants by an Inhibitor of the Tet(B) Antiport Protein, Mark Nelson and Stuart B. Levy, Antimicrobial Agents and Chemotherapy, July 1999, 1719-1724 Nomenclature for New Tetracycline Resistance Determinants, Stuart B. Levy et al, Antimicrobial Agents and Chemotherapy, June 1999, 1523-1524 “Superbugs,” The New York Times Magazine, August 2, 1998, 42-47 Multidrug Resistance following Expression of the Escherichia Coli MarA gene in Mycobacterium smegmatis, PF McDermott et al, Journal of Bacteriology, June 1998, 2995-2998 “The Challenge of Antibiotic Resistance,” Stuart B. Levy, Scientific American, March 1998, 46-53 Overexpression of mar A, SoxS, or acr AB produces resistance to triclosan in laboratory and clinical strains of Escherichia coli, Laura M. McMurry, Margret Oethinger, Stuart B. Levy, FEMS Microbiology Letters, 166, 1998-305-309 Reversing Tetracycline Resistance, A renaissance for the Tetracycline family of antibiotics, Stuart B. Levy and Mark Nelson, Resolving the Antibiotic Paradox, edited by Rosen and Mobashery. Kluwer Academic/Plenum Publishers, New York, 1998, 17-65 Regulation of Chromosomally Mediated Multiple Antibiotic Resistance: the mar regulon, Michael N. Alekshun and Stuart B. Levy, Antimicrobial Agents and Chemotherapy, Vol. 41, No. 10, October 1997, 2067-2075 Antibiotic Resistance: an ecological imbalance, Stuart B. Levy, Antibiotic Resistance, Origins, Evolution, Selection and Spread, 1997, Wiley, Chichester, 1-14 Antibiotics, the end of Miracle drugs, Newsweek, March 28, 1994 Molecular requirements for the inhibition of the tetracycline antiport protein and the effect of potent inhibitors on the growth of tetracycline-resistant bacteria, Mark L. Nelson, B.H. Park, Stuart B. Levy, Journal of Medicinal Chemistry, 1994 37:1355-1361 Inhibition of the tetracycline efflux protein by 13-thiosubstituted-5-hydroxy-6-deoxytetracyclines, Mark L. Nelson, B.H. Park, J.S. Andrews, V.A. Georgian, R.C. Thomas, Stuart B. Levy, Journal of Medicinal Chemistry, 1993 36:370-377 The Antibiotic Paradox. How miracle drugs are destroying the miracle, Stuart B. Levy, 1992, Plenum Publishing Corp., New York. |